Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2017-11-08
Target enrollment:
Participant gender:
Summary
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill
tumor cells. Giving vorinostat together with chemotherapy and radiation therapy may kill more
tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when
given together with cisplatin and radiation therapy in treating patients with stage III or
stage IVa squamous cell cancer of the oropharynx which is either unresectable or borderline
resectable.